| 000 | 01403 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250515222711.0 | ||
| 264 | 0 | _c20100701 | |
| 008 | 201007s 0 0 jpn d | ||
| 022 | _a0917-5857 | ||
| 024 | 7 |
_aCliCa1005735742 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTanaka, Yoshiya | |
| 245 | 0 | 0 |
_a[Secondary osteoporosis UPDATE. Rheumatoid arthritis and bone damage: trends in treatment]. _h[electronic resource] |
| 260 |
_bClinical calcium _cMay 2010 |
||
| 300 |
_a735-42 p. _bdigital |
||
| 500 | _aPublication Type: English Abstract; Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xcomplications |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xtherapeutic use |
| 650 | 0 | 4 | _aBone Remodeling |
| 650 | 0 | 4 | _aDenosumab |
| 650 | 0 | 4 |
_aDiphosphonates _xtherapeutic use |
| 650 | 0 | 4 |
_aGlucocorticoids _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMethotrexate _xtherapeutic use |
| 650 | 0 | 4 |
_aOsteoclasts _xphysiology |
| 650 | 0 | 4 |
_aOsteoporosis _xdrug therapy |
| 650 | 0 | 4 |
_aRANK Ligand _xtherapeutic use |
| 650 | 0 | 4 | _aSynovial Membrane |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 773 | 0 |
_tClinical calcium _gvol. 20 _gno. 5 _gp. 735-42 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/CliCa1005735742 _zAvailable from publisher's website |
| 999 |
_c19801174 _d19801174 |
||